



Recombinant Plague Vaccine

rF1V

Description

The Recombinant Plague Vaccine is intended to prevent pneumonic plague caused by aerosolized exposure to the bacterium, *Yersinia pestis*. The Recombinant Plague Vaccine (rF1V) is composed of the F1-V fusion protein formulated with an aluminum hydroxide adjuvant and delivered intramuscularly, as a three dose series, prior to potential aerosol exposure to *Yersinia pestis*. The initial development of this product was pioneered at the US Army Medical Research Institute of Infectious Diseases. Currently, Dynport Vaccine Company is the MCS-JVAP prime system contractor and regulatory sponsor for this advanced development effort. Food and Drug Administration approval is planned for FY2021.



Mission

Provide protection against weaponized plague bacteria.

Capabilities

- Biological Prophylaxis

Users

US Navy, US Marine Corps, US Army, US Air Force

Status

Engineering and Manufacturing Development - Anticipated Fielding: FY 2021 Q3

This Fact Sheet was cleared for public release on 4/25/2016.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@mail.mil,
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919